WallStreetZenWallStreetZen

NASDAQ: VERO
Venus Concept Inc Stock

$0.76-0.08 (-9.52%)
Updated Apr 23, 2024
VERO Price
$0.76
Fair Value Price
N/A
Market Cap
$4.83M
52 Week Low
$0.60
52 Week High
$4.70
P/E
-0.11x
P/B
-0.33x
P/S
0.08x
PEG
N/A
Dividend Yield
N/A
Revenue
$76.35M
Earnings
-$37.25M
Gross Margin
68.3%
Operating Margin
-39.85%
Profit Margin
-48.8%
Debt to Equity
-7.34
Operating Cash Flow
-$13M
Beta
1.19
Next Earnings
May 15, 2024
Ex-Dividend
N/A
Next Dividend
N/A

VERO Overview

Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes aesthetic device platforms, including Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; and Venus Viva, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss, a device for non-invasive lipolysis of the abdomen and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; and ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles. The company is headquartered in Toronto, Canada.

Zen Score

Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VERO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

VERO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
VERO is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
VERO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more VERO due diligence checks available for Premium users.

Be the first to know about important VERO news, forecast changes, insider trades & much more!

VERO News

Valuation

VERO fair value

Fair Value of VERO stock based on Discounted Cash Flow (DCF)
Price
$0.76
Fair Value
$2.43
Undervalued by
68.71%
VERO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

VERO price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.11x
Industry
29.66x
Market
41.92x

VERO price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-0.33x
Industry
3.71x

VERO's financial health

Profit margin

Revenue
$18.1M
Net Income
-$11.1M
Profit Margin
-61.3%
VERO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
VERO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$93.7M
Liabilities
$107.1M
Debt to equity
-7.34
VERO's short-term assets ($66.45M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VERO's long-term liabilities ($75.94M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VERO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VERO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$774.0k
Investing
-$27.0k
Financing
$1.3M
VERO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

VERO vs Medical Device Stocks

TickerMarket Cap1d %P/EP/B
VERO$4.83M-9.95%-0.11x-0.33x
BIOL$4.91M+0.67%-0.01x-19.88x
AFIB$5.02M+0.60%-0.06x-5.71x
HSDT$4.42M-1.87%-0.34x1.88x
XYLO$4.24M-9.96%-0.24x0.18x

Venus Concept Stock FAQ

What is Venus Concept's quote symbol?

(NASDAQ: VERO) Venus Concept trades on the NASDAQ under the ticker symbol VERO. Venus Concept stock quotes can also be displayed as NASDAQ: VERO.

If you're new to stock investing, here's how to buy Venus Concept stock.

What is the 52 week high and low for Venus Concept (NASDAQ: VERO)?

(NASDAQ: VERO) Venus Concept's 52-week high was $4.70, and its 52-week low was $0.60. It is currently -83.83% from its 52-week high and 26.25% from its 52-week low.

How much is Venus Concept stock worth today?

(NASDAQ: VERO) Venus Concept currently has 6,355,230 outstanding shares. With Venus Concept stock trading at $0.76 per share, the total value of Venus Concept stock (market capitalization) is $4.83M.

Venus Concept stock was originally listed at a price of $2,232.00 in Oct 12, 2017. If you had invested in Venus Concept stock at $2,232.00, your return over the last 6 years would have been -99.97%, for an annualized return of -73.57% (not including any dividends or dividend reinvestments).

How much is Venus Concept's stock price per share?

(NASDAQ: VERO) Venus Concept stock price per share is $0.76 today (as of Apr 23, 2024).

What is Venus Concept's Market Cap?

(NASDAQ: VERO) Venus Concept's market cap is $4.83M, as of Apr 24, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Venus Concept's market cap is calculated by multiplying VERO's current stock price of $0.76 by VERO's total outstanding shares of 6,355,230.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.